TxCell to present at ROTH Capital Partners investor conference in US
Posted: 26 February 2015 | TxCell
TxCell invited to speak at largest US meeting for investors in emerging growth companies…
TxCell SA (FR0010127662 – TXCL), a biotechnology company developing innovative, cost-effective, personalized T cell immunotherapies using antigen specific regulatory T-cells (Ag-Tregs) for severe chronic inflammatory and autoimmune diseases, today announces that Damian Marron, CEO, TxCell, will present to selected leading institutional investors at the 27th Annual ROTH Conference 2015. The conference will take place on March 8 – 11, 2015 in Dana Point, CA, USA.
TxCell’s corporate presentation is scheduled for Wednesday, March 11, 2015 at 10:30 a.m. PST at The Ritz Carlton, Track 4, The Colonnade, 1 Ritz Carlton Dr, Dana Point, CA.
In the presentation, Damian Marron will provide an overview of TxCell and its personalized T cell immunotherapy platform ASTrIA. Additional details will also be provided to institutional investors in one on one meetings at the conference. Topics covered include development of Ovasave(R), TxCell’s lead product candidate in refractory Crohn’s disease, for which a multinational placebo-controlled phase IIb clinical study is ongoing, Col-Treg, TxCell’s second product candidate developed in autoimmune uveitis, a rare eye disease for which a phase I/II proof of principle clinical trial is planned to start in the first half of 2015, and TxCell’s innovative, cost-effective business model. Details of the next milestones for TxCell, including those of the EUR 76 million partnership with Ferring / Trizell will also be provided.
The Roth Capital Partners conference enables CEOs from small-cap growth companies to make presentations to leading institutional investors. This annual event is the largest in the US for emerging growth companies. It provides a concentrated forum where institutional investors can meet the executives of growth companies. Investors and companies are personally selected by Roth Capital’s research team.
“TxCell has continued to develop rapidly since its IPO last year. We are now in a very strong position, with one of the most advanced, innovative personalized T-cell immunotherapy multi-product pipelines. This is also backed up by an extensive patent portfolio, a partnership with a major pharmaceutical company with a recent extension, a GMP validated manufacturing process and a robust discovery platform,” said Damian Marron, CEO TxCell. “In addition, we have achieved additional important milestones. Hence it is very important to inform and update investors and members of the US financial community who are active in the small-cap markets at the respected ROTH Conference. This will give them an additional unique insight into investment hypotheses for TxCell’s advanced therapies-based treatments.”